Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetes

Trial StartPIMAPositive

AI Analysis

Summary

Aqua Medical appoints MedTech veteran Bob Haggerty as CEO as the company begins treating its first patient in a U.S. pilot study of PIMA for type 2 diabetes treatment.

Clinical Trial Data

Phase

pilot

Outcome Details

First patient treated in U.S. pilot study

Importance:4/10

Sentiment:

0.40

management changeclinical trialtype 2 diabetesMedTechpatient enrollment

Related Companies

$MDCE $TRAX

Read the original article

Published by PR Newswire Biotech on August 4, 2026 2:00 PM

Read Original